---
title: "Wolwo Pharma: Application for clinical trial of dermatitis diagnostic patch 02 has been accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230459435.md"
description: "According to the Zhitong Finance APP, Wolwo Pharma announced that the company has received the \"Acceptance Notice\" issued by the National Medical Products Administration, and the clinical trial application for the \"Dermatitis Diagnostic Patch 02\" submitted by the company has been officially accepted. The relevant indications are: for patch testing, to assist in the diagnosis of allergic contact dermatitis related to sensitization by carbamates, p-phenylenediamine, and formaldehyde"
datetime: "2025-03-04T09:44:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230459435.md)
  - [en](https://longbridge.com/en/news/230459435.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230459435.md)
generator: "portal-rs"
---

# Wolwo Pharma: Application for clinical trial of dermatitis diagnostic patch 02 has been accepted

According to the Zhitong Finance APP, Wolwo Pharma (300357.SZ) announced that the company has received the "Acceptance Notice" issued by the National Medical Products Administration, and the clinical trial application for the "Dermatitis Diagnostic Patch 02" submitted by the company has been officially accepted. The relevant indications are: for patch testing, to assist in the diagnosis of allergic contact dermatitis related to sensitization by carbamates, p-phenylenediamine, and formaldehyde

### Related Stocks

- [300357.CN](https://longbridge.com/en/quote/300357.CN.md)

## Related News & Research

- [US FDA is working with manufacturers to boost estradiol patch supply amid access concerns](https://longbridge.com/en/news/297917790.md)
- [NeuroThera Labs seeks FDA orphan drug status for adult Tourette treatment SCI-110](https://longbridge.com/en/news/297783543.md)
- [Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex](https://longbridge.com/en/news/298029888.md)
- [08:15 ETLegacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical Drugs](https://longbridge.com/en/news/297912207.md)
- [Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™](https://longbridge.com/en/news/297635298.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**